Details for Patent: 8,217,007
✉ Email this page to a colleague
Which drugs does patent 8,217,007 protect, and when does it expire?
Patent 8,217,007 protects KORSUVA and is included in one NDA.
This patent has forty-nine patent family members in twenty-five countries.
Summary for Patent: 8,217,007
| Title: | Synthetic peptide amides |
| Abstract: | The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P.sub.450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure of formula I: ##STR00001## Pharmaceutical compositions containing these compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions. Such treatable pain includes visceral pain, neuropathic pain and hyperalgesia. Inflammation associated with conditions such as IBD and IBS, ocular and otic inflammation, other disorders and conditions such as pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma are treatable or preventable with the pharmaceutical compositions of the invention. |
| Inventor(s): | Schteingart; Claudio D. (San Diego, CA), Menzaghi; Frederique (Rye, NY), Jiang; Guangcheng (San Diego, CA), Alexander; Roberta Vezza (San Diego, CA), Sueiras-Diaz; Javier (La Jolla, CA), Spencer; Robert H. (New Hope, PA), Chalmers; Derek T. (Riverside, CT), Luo; Robert Zhiyong (New City, NY) |
| Assignee: | Cara Therapeutics, Inc. (Shelton, CT) |
| Application Number: | 12/786,686 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 8,217,007
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cara Therap | KORSUVA | difelikefalin acetate | SOLUTION;INTRAVENOUS | 214916-001 | Aug 23, 2021 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF MODERATE-TO-SEVERE PRURITUS ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD-AP) IN ADULTS UNDERGOING HEMODIALYSIS (HD) | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,217,007
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2064228 | ⤷ Subscribe | 301199 | Netherlands | ⤷ Subscribe |
| European Patent Office | 2064228 | ⤷ Subscribe | CA 2022 00045 | Denmark | ⤷ Subscribe |
| European Patent Office | 2064228 | ⤷ Subscribe | PA2022522 | Lithuania | ⤷ Subscribe |
| European Patent Office | 2064228 | ⤷ Subscribe | LUC00282 | Luxembourg | ⤷ Subscribe |
| European Patent Office | 2064228 | ⤷ Subscribe | 2022C/546 | Belgium | ⤷ Subscribe |
| European Patent Office | 2064228 | ⤷ Subscribe | C20220035 00379 | Estonia | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
